CN109734600B - 一种手性β羟基酸酯类化合物的合成方法 - Google Patents

一种手性β羟基酸酯类化合物的合成方法 Download PDF

Info

Publication number
CN109734600B
CN109734600B CN201811536129.9A CN201811536129A CN109734600B CN 109734600 B CN109734600 B CN 109734600B CN 201811536129 A CN201811536129 A CN 201811536129A CN 109734600 B CN109734600 B CN 109734600B
Authority
CN
China
Prior art keywords
acid ester
hydroxy acid
chiral
compound
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811536129.9A
Other languages
English (en)
Other versions
CN109734600A (zh
Inventor
蒋俊
刘洪鑫
王娜
李娟�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wenzhou University
Original Assignee
Wenzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenzhou University filed Critical Wenzhou University
Priority to CN201811536129.9A priority Critical patent/CN109734600B/zh
Publication of CN109734600A publication Critical patent/CN109734600A/zh
Priority to US16/702,555 priority patent/US10906860B2/en
Application granted granted Critical
Publication of CN109734600B publication Critical patent/CN109734600B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1815Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1815Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
    • B01J31/182Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine comprising aliphatic or saturated rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1825Ligands comprising condensed ring systems, e.g. acridine, carbazole
    • B01J31/183Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline
    • B01J31/1835Ligands comprising condensed ring systems, e.g. acridine, carbazole with more than one complexing nitrogen atom, e.g. phenanthroline comprising aliphatic or saturated rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2204Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208Oxygen, e.g. acetylacetonates
    • B01J31/2226Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • B01J31/2243At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/3411,2-additions, e.g. aldol or Knoevenagel condensations
    • B01J2231/342Aldol type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues, to aldehydes or ketones
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • B01J2531/0241Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • B01J2531/0241Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
    • B01J2531/0244Pincer-type complexes, i.e. consisting of a tridentate skeleton bound to a metal, e.g. by one to three metal-carbon sigma-bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • B01J2531/0241Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
    • B01J2531/0252Salen ligands or analogues, e.g. derived from ethylenediamine and salicylaldehyde
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261Complexes comprising ligands with non-tetrahedral chirality
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/10Complexes comprising metals of Group I (IA or IB) as the central metal
    • B01J2531/16Copper
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/10Complexes comprising metals of Group I (IA or IB) as the central metal
    • B01J2531/17Silver
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/824Palladium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/847Nickel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种手性β羟基酸酯类化合物的合成方法,其特征在于,所述方法包含下列步骤:以醛类化合物与丙二酸单烷基酯为原料,在有机溶剂中,金属与手性配体为催化剂的条件下直接充分反应,反应结束后反应液经分离纯化得到所述的高立体选择性的β羟基酸酯类化合物。其有益效果主要体现在:1,操作简单;2,能快速构建高立体选择性的β羟基酸酯骨架结构分子;3,反应收率高,立体选择性好。故本发明具有较高的基础研究意义、工业生产价值和社会经济效益。

Description

一种手性β羟基酸酯类化合物的合成方法
技术领域
本发明涉及有机化学领域,特别是指一种手性β羟基酸酯类化合物及其通过脱羧aldol加成的合成方法。
背景技术
手性β羟基酸酯及其衍生物广泛存在于众多天然产物和药物分子中,是有机合成中以及药物开发工程中的重要中间体。手性β羟基酸酯是合成手性β羟基酸、β-氨基酸、青霉素、生物信息素等的重要前体。手性β-羟基取代羧酸酯是众多天然产物(胡桃霉素A、芦荟酸等)的主体估价以及诸多药物分子尤其是抗抑郁和多动症的精神类药物(氟西汀、度洛西汀、阿托西汀)的重要合成中间体,并且可以直接快速高效的合成手性药物分子Phenylpropanoid,因此,开发绿色高效的合成手性β-取代羧酸酯及其衍生物的合成策略具有重要意义。
从现有的报道来看,构建重要的有机合成中间体与众多药物活性分子的核心骨架的手性β-羟基取代的羧酸酯类化合物利用不对称Mukaiyama Aldol反应和β-酮羧酸酯通过不对称氢化还原来实现。但是,由于对该类反应认识的局限,存在底物需提前构建、产物结构官能团兼容性受限、反应条件不温和等缺陷。在此基础上,设计开发新的底物结构,实现一类结构新颖的手性β羟基酸酯类化合物的合成具有重要的的理论研究意义和实际应用价值。
此外,现有的报道具有诸多局限,构建高立体选择性的手性β羟基酸酯类化合物以及含多官能团的手性β羟基酸酯类化合物的报道极少。基于此,为了进一步了解脱羧加成反应的性质,拓展该反应类型和应用,为手性β羟基酸酯骨架结构分子开发设计新的合成途径,对于药物分子的开发设计以及基础方法学研究都具有重要的推动作用。
发明内容
本发明实施例所要解决的技术问题在于,提供一种手性β羟基酸酯的合成方法。该方法操作简单、工艺合理、低毒性、反应条件温和、反应收率高、产品质量好、具有高立体选择性的手性β羟基酸酯类化合物合成方法。
为实现上述目的,本发明的技术方案是该方法包括:
以醛类化合物与丙二酸单烷基酯为原料,在有机溶剂中,以金属化合物、有机酸盐以及手性配体为催化剂,进行脱羧aldol加成反应,反应完毕后经过分离纯化得到的手性β羟基酸酯类化合物,该手性β羟基酸酯类化合物的结构式为:
Figure GDA0002529905550000021
所述醛类化合物的结构式为:
R1-CHO
所述丙二酸单烷基酯的结构式为
Figure GDA0002529905550000022
所述的R1选自下列之一:烷基、带氟、氯、溴、硝基、烷基、烷氧基等取代的苯基或其它类芳基;所述的R1优选为对硝基苯基;
所述的R2选自下列之一:甲基、乙基、丙基、丁基、异丙基、叔丁基;所述的R2优选为烷基;
所用的有机溶剂为不与反应物和产物发生反应的有机溶剂。
进一步设置是所述的有机溶剂选自下列一种或者任意几种的组合:二氯甲烷、乙酸乙酯、四氢呋喃、乙腈、甲苯、甲醇、氯仿。
进一步设置是所用有机溶剂的质量是原料的1-200倍,优选为20-50倍。
进一步设置是所述的醛类化合物与丙二酸单烷基酯的摩尔投料比为1:1-5,优选为1:2。
进一步设置是所述的催化剂中金属化合物选自下列一种或者任意几种的组合:三氟甲磺酸铜、硫酸铜、醋酸铜、醋酸钯、氟化亚铁、醋酸银、四水合醋酸镍、乙酰丙酮镍、氟化镍、六水合氯化镍、硫酸镍、高氯酸镍、双三苯基膦氯化镍。
进一步设置是所述的催化剂体系中手性配体选自下列一种或者任意几种的组合
Figure GDA0002529905550000031
优选为为手性配体L5。
进一步设置是所述的催化剂体系中盐选自下列一种或者任意几种的组合;
Figure GDA0002529905550000032
所述的催化剂体系中金属与盐的摩尔比为1:1-3。
进一步设置是所述的催化剂与醛类化合物比例为1wt%-20wt%,优选为10wt%,所述的催化剂体系中金属与手性配体的摩尔比为1:1-1.5,优选为1:1.1。
本发明中,反应温度为0-60℃,优选为20-30℃,反应时间一般在3-72小时,优选为40-60小时。
本发明所述的分离纯化采用的是柱层析分离纯化法。反应结束后所得反应液蒸出溶剂,经湿法上样进行柱层析分离纯化干燥即得目标产物β羟基酸酯类化合物。进一步,淋洗液为石油醚与乙酸乙酯混合物,石油醚与乙酸乙酯比例为20:1-2:1,优选为10:1-5:1。
优选实施例中,本发明是首次利用六水合氯化镍、邻硝基苯甲酸钾和噁唑啉骨架的手性配体L5催化普通醛与丙二酸单烷基酯发生脱羧aldol加成反应,合成手性β羟基酸酯类化合物。其有益效果主要体现在:1,操作简单;2,成本低廉;3,反应收率高;4,具有高立体选择性。故本发明具有较高的基础研究价值和社会经济效益。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,根据这些附图获得其他的附图仍属于本发明的范畴。
图1本发明实施例中反应产物结构式图;
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明作进一步地详细描述。
优选实施例
本发明具体推荐所述的手性β羟基酸酯类化合物的化学合成方法按照如下步骤进行:室温条件下,将金属催化剂与有机酸盐加入反应釜中,用溶剂A充分溶解后,充分搅拌30-60分钟,再向反应釜中加入手性配体充分搅拌30-60分钟,然后加入普通醛与丙二酸单烷基酯,在20-30℃的条件下,搅拌使其反应40-72小时,实时监测反应进程,反应完毕后分离纯化,干燥后即得到所述的手性β羟基酸酯类目标化合物。
实施例1
R1为对硝基苯基的醛,R2为甲基的丙二酸单甲酯与催化剂的物质的量比为1.0:2.0:0.1投料,即底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、四水合醋酸镍49.6mg(0.2mmol)、手性配体L1 72.6mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与手性配体L1加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中加入对硝基苯甲醛与丙二酸单甲酯,在30℃的条件下,搅拌使其反应72小时后结束。
反应完毕后分离纯化,干燥后得到白色固体,即为所述的手性β羟基酸酯类目标化合物1a 101.3mg,收率45%,对映选择性过量为2%ee,纯度为99.0%具体结构为:
Figure GDA0002529905550000051
数据表征:
大赛璐手性柱AS,己烷/异丙醇=90/10,流速1.0mL/min,25℃:保留时间tR(大峰)=17.1分钟,tR(小峰)=21.3分钟。1H NMR(500MHz,CDCl3)δ8.20(d,J=8.7Hz,2H),7.57(d,J=8.6Hz,2H),5.29-5.20(m,1H),3.76(d,J=5Hz,2H),3.74(s,3H),2.83-2.69(m,2H)。13C NMR(126MHz,CDCl3)δ172.27、149.77、147.29、126.52、123.76、69.36、52.10、42.82。
实施例2
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、四水合醋酸镍49.6mg(0.2mmol)、手性配体L3 73.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与手性配体L3加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中加入对硝基苯甲醛与丙二酸单甲酯,在30℃的条件下,搅拌使其反应72小时后结束。
其余同实施例1,得目标产物1a 60.1mg,收率27%,对映选择性过量为9%ee,纯度为98.8%。
实施例3
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、四水合醋酸镍49.6mg(0.2mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与手性配体L5加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中加入对硝基苯甲醛与丙二酸单甲酯,在30℃的条件下,搅拌使其反应72小时后结束。
其余同实施例1,得目标产物1a 128.3mg,收率57%,对映选择性过量为60%ee,纯度为99.8%。
实施例4
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、四水合醋酸镍49.6mg(0.2mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与手性配体L5加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中加入对硝基苯甲醛与丙二酸单甲酯,在20℃的条件下,搅拌使其反应72小时后结束。
其余同实施例1,得目标产物1a83.3mg,收率37%,对映选择性过量为77%ee,纯度为99.6%。
实施例5
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、醋酸镍35.2mg(0.2mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与手性配体L5加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中加入对硝基苯甲醛与丙二酸单甲酯,在20℃的条件下,搅拌使其反应72小时后结束。
其余同实施例1,得目标产物1a 105.8mg,收率47%,对映选择性过量为77%ee,纯度为99.5%。
实施例6
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、醋酸镍35.2mg(0.2mmol)、邻硝基苯甲酸钠盐75.6mg(0.4mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与邻硝基苯甲酸钠盐加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中手性配体L5即(4)继续搅拌30-60分钟,然后加入普通醛与丙二酸单烷基酯,在20℃的条件下,搅拌使其反应24小时后结束。
其余同实施例1,得目标产物1a 119.3mg,收率53%,对映选择性过量为80%ee,纯度为99.2%。
实施例7
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、六水合氯化镍47.2mg(0.2mmol)、邻硝基苯甲酸钠盐75.6mg(0.4mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
其余同实施例6,得目标产物1a 121.5mg,收率54%,对映选择性过量为88%ee,纯度为99.7%。
实施例8
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、六水合氯化镍47.2mg(0.2mmol)、邻硝基苯甲酸钾盐82mg(0.4mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
其余同实施例6,得目标产物1a 126mg,收率56%,对映选择性过量为90%ee,纯度为99.3%。
实施例9
底物对硝基苯甲醛302mg(2mmol)、丙二酸单甲酯472mg(4mmol)、六水合氯化镍47.2mg(0.2mmol)、邻硝基苯甲酸钾盐82mg(0.4mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃6.0g,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与邻硝基苯甲酸钠盐加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中手性配体L5即(4)继续搅拌30-60分钟,然后加入普通醛与丙二酸单烷基酯,在15℃的条件下,搅拌使其反应60小时后结束。
其余同实施例1,得目标产物1a 200.3mg,收率89%,对映选择性过量为92%ee,纯度为99.6%。
实施例10-41,对应产物1b-1ag。
底物为不同取代基的醛(2mmol)、丙二酸单烷基酯(4mmol)、六水合氯化镍47.2mg(0.2mmol)、邻硝基苯甲酸钾盐82mg(0.4mmol)、手性配体L5即(4)86.5mg(0.22mmol);有机溶剂为四氢呋喃,其总用量为底物对硝基苯甲醛的20倍。
室温条件下,将金属催化剂与邻硝基苯甲酸钠盐加入反应釜中,用四氢呋喃充分溶解后,充分搅拌30-60分钟,再向反应釜中手性配体L5即(4)继续搅拌30-60分钟,然后加入普通醛与丙二酸单烷基酯,在15℃的条件下,搅拌使其反应60小时后结束。
其余同实施例1,得目标产物1,结果如图1所示:
实施例9-41(1a-1ag)的具体表征数据:
实施例9
3-羟基-3-(4-硝基苯基)丙酸甲酯(1a):产率89%,[α]D 25=+18.97(CHCl3中c=0.26),
Figure GDA0002529905550000091
8.6Hz,2H),5.29-5.20(m,1H),3.76(d,J=5Hz,2H),3.74(s,3H),2.83-2.69(m,2H)。13CNMR(126MHz,CDCl3)δ172.27、149.77、147.29、126.52、123.76、69.36、52.10、42.82。
实施例103-羟基-3-(4-硝基苯基)丙酸乙酯(1b):收率81%,[α]D25=+21.92(CHCl3中c=0.26),
Figure GDA0002529905550000101
7.54(d,J=8.6Hz,1H),5.21(dt,J=7.9,3.8Hz,1H),4.16(q,J=7.1Hz,2H),3.78(d,J=3.6Hz,1H)),2.83-2.58(m,2H),1.24(t,J=7.1Hz,3H).13C NMR(126MHz,CDCl3)δ171.90,149.82,147.43,126.52,123.73,69.38,61.20,42.98,14.09。
实施例11
3-羟基-3-(4-硝基苯基)丙酸丙酯(3c):收率90%;[α]D25=-17.88(CHCl3中c=0.38),对映体过量:
Figure GDA0002529905550000102
(s,1H),4.06(t,J=6.7Hz,2H),3.79(s,1H),2.83-2.57(m,2H),1.67-1.47(m,2H),0.90(t,J=7.4Hz,3H).13C NMR(126MHz,CDCl3)δ172.00,149.84,147.41,126.53,123.72,69.38,66.78,42.94,21.84,10.26。
实施例12
3-羟基-3-(4-硝基苯基)丙酸丁酯(1d):收率89%,[α]D25=-17.77(CHCl3中c=0.69),对映体过量:
Figure GDA0002529905550000103
(dd,J=7.9,3.8Hz,1H),4.11(t,J=6.7Hz,2H),3.77(d,J=3.6Hz,1H),2.78-2.65(m,2H),1.62-1.52(m,2H),1.38-1.28(m,2H),0.90(t,J=7.4Hz,3H).13C NMR(126MHz,CDCl3)δ171.98、149.81、147.43、126.52、123.72、69.39、65.08、42.95、30.50、19.03、13.59。
实施例13
3-羟基-3-(4-硝基苯基)丙酸异丙酯(1e):产率为87%,[α]D25
Figure GDA0002529905550000104
min,tR(次要)=22.1分钟1H NMR(500MHz,CDCl3)δ8.19(d,J=8.7Hz,2H),7.55(d,J=8.5Hz,2H),5.24-5.17(m,1H),5.05(dt,J=12.5,6.3Hz,1H),3.78(d,J=3.1Hz,1H),2.78-2.60(m,2H),1.23(dd,J=7.7,6.6Hz,6H).13C NMR(126MHz,CDCl3)δ171.50,149.80,147.15,126.52,123.73,69.41,68.95,43.17,21.74,21.72。
实施例14
3-羟基-3-(4-硝基苯基)丙酸叔丁酯(1f):产率75%,[α]D25=-49.62(CHCl3中c=0.13),对映体过
Figure GDA0002529905550000111
Hz,1H),3.85(s,1H),2.65(qd,J=16.6,6.3Hz,2H),1.45(s,9H).13C NMR(126MHz,CDCl3)δ171.41,149.89,147.40,126.52,123.69,82.20,69.49,43.81,28.05。
实施例15
3-(4-氟苯基)-3-羟基丙酸甲酯(1g):产率71%,[α]D25=-20.41(CHCl3中c=0.29),对映体过量:
Figure GDA0002529905550000112
(s,3H),3.39(d,J=2.6Hz,1H),2.70(qd,J=16.3,13C NMR(126MHz,CDCl3)δ172.58、163.30、161.34、138.33、127.39、127.33、115.45、115.28、69.68、51.85、43.19。
实施例16
3-(3-氟苯基)-3-羟基丙酸甲酯(1h):产率74%,[α]D25=-41.61(CHCl3中c=0.26),对映体过量:
Figure GDA0002529905550000113
2.3Hz,1H),5.06-4.94(m,1H),3.70(d,J=3.7Hz,1H),3.59(s,3H),2.65-2.54(m,2H).13CNMR(126MHz,CDCl3)δ172.46,163.91,161.96,145.45,145.40,130.07,130.00,121.23,121.20,114.61,114.45,112.76,112.59、69.64、69.62、51.87、43.15。
实施例17
3-(2-氟苯基)-3-羟基丙酸甲酯(1i):产率72%,[α]D25=-62.79(CHCl3中c=0.26),对映体过量:
Figure GDA0002529905550000114
6.94-6.85(m,1H),5.35-5.24(m,1H),3.72-3.63(m,1H),3.59(s,3H),2.64(qd,J=16.3,6.3Hz,2H).13C NMR(126MHz,CDCl3)δ172.58,160.41,158.46,129.72,129.62,129.14,129.08,127.25、127.22、124.35、124.32、115.28、115.11、64.52、64.50、51.83、41.89。
实施例18
3-(4-氯苯基)-3-羟基丙酸甲酯(1j):产率76%,[α]D25=-44.17(CHCl3中c=0.37),对映体过量:
Figure GDA0002529905550000121
2.79-2.61(m,2H).13C NMR(126MHz,CDCl3)δ172.54,141.07,133.50,128.69,127.07、69.62、51.94、43.08。
实施例19
3-(3-溴苯基)-3-羟基丙酸甲酯(1k):产率72%,[α]D25=-46.40(CHCl3中c=0.52),对映体过量:
Figure GDA0002529905550000122
(t,J=7.8Hz,1H),5.13-5.05(m,1H),3.71(s,3H),3.58(s,1H),2.75-2.64(m,2H).13C NMR(126MHz,CDCl3)δ172.47,144.92,130.85,130.12,128.86,124.28,122.67,69.59,51.95,43.08。
实施例20
3-(2-溴苯基)-3-羟基丙酸甲酯(1l):71%产率,[α]D25=-41.67(c=0.25在CHCl3中),对映体过量:
Figure GDA0002529905550000123
J=7.8,1.5Hz,1H),5.43(dd,J=9.8,2.2Hz,1H),3.72(s,3H),3.68(s,1H),2.85(dd,J=16.5,2.6Hz,1H),2.55(dd,J=16.5,9.8Hz,1H).13C NMR(126MHz),CDCl3)δ172.71、141.53、132.65、129.10、127.84、127.33、121.40、69.25、51.95、41.47。
实施例21
3-(4-氰基苯基)-3-羟基丙酸甲酯(1m):产率72%,[α]D25=-44.73(CHCl3中c=0.16),对映体过量:
Figure GDA0002529905550000124
1H),3.72(s,3H),2.72(d,J=6.4Hz,2H).13C NMR(126MHz),CDCl3)δ172.24、147.94、132.36、126.42、118.65、111.47、69.51、52.05、42.89。
实施例22
3-(3-氰基苯基)-3-羟基丙酸甲酯(1n):产率72%,[α]D25=-45.97(CHCl3中c=0.34),对映体过量:
Figure GDA0002529905550000131
(t,J=7.7Hz,1H),5.15(d,J=1.6Hz,1H),3.72(s,3H)),3.63(d,J=2.7Hz,1H),2.71(d,J=6.4Hz,2H).13C NMR(126MHz,CDCl3)δ172.34,144.07,131.40,130.14,129.41,129.35,118.64,112.67,69.24、52.07、42.87。
实施例23
3-(2-氰基苯基)-3-羟基丙酸甲酯(1o):产率70%,[α]D25=-50.67(CHCl3中c=0.13),对映体过量:
Figure GDA0002529905550000132
Hz,1H),6.91(s,1H),4.93(dd,J)=10.5,3.0Hz,1H),3.78(s,3H),3.03(dd,J=17.1,3.4Hz,1H),2.47(dd,J=17.0,10.6Hz,1H).13C NMR(126MHz,CDCl3)δ171.48、170.47、146.01、132.00、131.91、128.58、123.96、122.38、52.99、52.15、39.34。
实施例24
4-甲酸甲酯基-1’羟基-苯丙酸甲酯(1p):74%收率,[α]D25=-32.39(CHCl3中c=0.21),对映体过量:
Figure GDA0002529905550000133
1H),3.89(s,3H),3.70(s,3H),3.53(s,1H),2.77-2.68(m,2H).13C NMR(126MHz,CDCl3)δ172.02、166.83、147.60、129.86、129.60、125.59、69.87、52.07、51.93、42.99。
实施例25
3-(1-羟基-3-甲氧基-3-氧代丙基)苯甲酸甲酯(1q):收率76%,[α]D25=-55.47(CHCl3中c=0.14),
Figure GDA0002529905550000134
=7.5Hz,1H),7.41(t,J=7.7Hz,1H),5.17(dd,J=8.4、4.3Hz,1H),3.89(d,J=0.7Hz,3H),3.70(s,3H),2.79-2.68(m,2H).13C NMR(126MHz,CDCl3)δ172.55,166.90,143.00,130.44,130.23,128.99,128.67,126.85、69.85、52.13、51.93、43.07。
实施例26
3-(4-甲酰基苯基)-3-羟基丙酸甲酯(1r):产率79%,[α]D25=-32.93(CHCl3中c=0.50),对映体过
Figure GDA0002529905550000141
2H),5.17(s,1H),3.78-3.73(m,1H),3.67(s,3H),2.73-2.67(m,2H).13C NMR(126MHz,CDCl3)δ191.91,172.30,149.46,135.87,129.99,126.26,69.81,51.96,43.00。
实施例27
3-(3-甲酰基苯基)-3-羟基丙酸甲酯(1s):产率85%,[α]D25=-31.79(CHCl3中c=0.26),对映体过
Figure GDA0002529905550000142
(d,J=7.7Hz,1H),7.52(t,J=7.6Hz,1H),5.21(t,J=7.8Hz,1H)),3.72(s,3H),3.58(d,J=3.5Hz,1H),2.80-2.71(m,2H).13C NMR(126MHz,CDCl3)δ192.10,172.50,143.74,136.43,131.74,129.28,129.14、126.84、69.64、51.98、42.97。
实施例28
3-羟基-3-(2-甲氧基苯基)丙酸甲酯(1t):收率70%,[α]D25=-43.00(CHCl3中c=0.13),对映体过
Figure GDA0002529905550000143
J=8.2Hz,1H),5.39-5.31(m,1H),3.84(s,3H)),3.71(s,3H),3.48(d,J=4.2Hz,1H),2.82(dd,J=16.1,3.4Hz,1H),2.71(dd,J=16.1,9.3Hz,1H).13C NMR(126MHz,CDCl3)δ172.96,156.04,130.58,128.60,126.54,120.82,110.36,66.55,55.25,51.71,41.61。
实施例29
3-羟基-3-(3-甲氧基苯基)丙酸甲酯(1u):收率71%,[α]D25=-16.46(CHCl3中c=0.24),对映体过
Figure GDA0002529905550000144
25℃:tR(次要)=19.2min,tR(主要)=21.9分钟1H NMR(500MHz,CDCl3)δ7.26(dd,J=10.2,5.5Hz,1H),6.93(d,J=8.5Hz,2H),6.82(dd,J=8.1,1.8Hz,1H),5.10(dd,J=9.0,3.7Hz,1H),3.80(s,3H)),3.71(s,3H),3.36(br,1H),2.72(qd,J=16.3,6.4Hz,2H).13CNMR(126MHz,CDCl3)δ172.70,159.84,144.29,129.59,117.90,113.39,111.17、70.25、55.22、51.86、43.22。
实施例30
3-([1,1'-联苯]-4-基)-3-羟基丙酸甲酯(1v):产率为72%,[α]D25=9.35(CHCl3中c=0.36),对映体
Figure GDA0002529905550000151
(m,1H),3.75(s,3H),3.26(d,J=3.4Hz,1H),2.80(qd,J=16.4,6.4Hz,2H).13C NMR(126MHz,CDCl3)δ172.75,141.51,140.84,140.75,128.78,127.35,127.33,127.09,126.12,51.90,43.10。
实施例31
3-(2-乙炔基苯基)-3-羟基丙酸甲酯(1w):产率75%,[α]D25=-45.20(CHCl3中c=0.24),对映体过
Figure GDA0002529905550000152
1H),5.57(d,J=9.7Hz,1H),3.74(s,3H)),3.48(d,J=3.1Hz,1H),3.36(s,1H),2.90(dd,J=16.5,2.7Hz,1H),2.66(dd,J=16.5,9.8Hz,1H).13C NMR(126MHz,CDCl3)δ172.91,144.85,132.89,129.38,127.25,125.29,119.19,82.79,81.00,68.26,51.88,41.95。
实施例32
3,4-氧代亚甲基-5甲氧基-1’羟基-苯丙酸甲酯(1x):收率71%,[α]D25=-38.30(CHCl3中c=0.20),对映体过量:90%,Daicel Chiralpak AD,己烷/异丙醇=95/5,流速1.0mL/min,25℃:tR(次要)=35.6min,tR(主要)=44.6min。1H NMR(500MHz,CDCl3)δ6.57(d,J=14.2Hz,2H),5.96(s,2H),5.04(d,J=6.3Hz,1H),3.90(s,3H),3.73(s,3H),3.20(s,1H),2.70(qd,J=16.3,6.4Hz,2H).13C NMR(126MHz,CDCl3)δ172.66,149.00,143.67,137.32,134.75,105.30,101.49,99.93,70.32,56.63,51.89、43.31。
实施例33
3-羟基-3-(萘-2-基)丙酸甲酯(1y):产率81%,[α]D25=-13.56(CHCl3中c=0.23),对映体过量:91%,Daicel Chiralpak AD,己烷/异丙醇=95/5,流速1.0mL/min,25℃:tR(次
Figure GDA0002529905550000161
3H),3.45(d,J=2.9Hz,1H),2.83(qd,J=16.4,6.4Hz,2H).13C NMR(126MHz,CDCl3)δ172.77,139.88,133.31,133.06,128.43,128.03,127.69,126.25,126.02,124.47,123.69,70.46(s),51.92,43.14.
实施例34
3-羟基-3-(萘-1-基)丙酸甲酯(1z):收率82%,[α]D25=-53.54(CHCl3中c=0.13),对映体过量:86%,
Figure GDA0002529905550000162
1H),7.58-7.41(m,3H),5.94(d,J=9.6Hz,1H),3.78(s,3H),3.34(d,J=3.1Hz,1H),2.94(dd,J=16.6,2.9Hz,1H),2.86(dd,J 13C NMR(126MHz,CDCl3)δ173.06,137.97,133.80,129.97,129.04,128.35,126.32,125.64,125.52,122.95,122.75,67.37,51.99,42.56。
实施例35
3-(蒽-9-基)-3-羟基丙酸甲酯(1aa):收率78%,[α]D25=-21.63(CHCl3中c=0.26),对映体过量:
Figure GDA0002529905550000163
CDCl3)172.97、132.28、131.68、129.38、129.19、128.57、125.94、124.85、124.60、77.29、77.04、76.78、67.32、52.00、41.59。
实施例36
4-硝基3’-羟基-苯1’2’-戊烯酸甲酯(1ab):产率为79%,[α]D25=-18.12(CHCl3中c=0.26),对
Figure GDA0002529905550000164
2H),6.77(d,J=15.9Hz,1H),6.41(dd,J=15.9,5.4Hz,1H),4.78(s,1H),3.75(s,3H),3.23(s,1H),2.72(dd,J=16.5,3.8Hz,1H),2.64(dd,J=16.5,8.5Hz,1H).13C NMR(126MHz,CDCl3)δ172.42、147.15、142.96、134.70、128.55、127.08、124.00、77.25、77.00、76.75、68.26、51.98、40.94。
实施例37
3-羟基-4-氧代-4-苯基丁酸甲酯(1ac):产率71%,[α]D25=+15.01(c=0.12在MeOH中),对映体过
Figure GDA0002529905550000171
2H),5.41(d,J=5.0Hz,1H),4.04(s,1H),3.67(s,3H)),2.86(dd,J=15.9,3.4Hz,1H),2.60(dd,J=15.9,8.0Hz,1H).13C NMR(126MHz,CDCl3)δ199.85,170.90,134.05,133.42,128.95,128.64,70.22、52.06、40.17。
实施例38
(1ad):产率76%,[α]D25=-13.32(CHCl3中c=0.51),对映体过量:84%,DaicelChiralpak
Figure GDA0002529905550000172
CDCl3)δ172.39,91.60,68.56,68.17,68.11,66.56,66.47,66.04,51.81,42.65,29.71。
实施例39
3-羟基-3-(噻吩-2-基)丙酸甲酯(1ae):产率76%,[α]D25=-13.56(CHCl3中c=0.15),对映体过量:
Figure GDA0002529905550000173
J=7.6,6.1Hz,1H),3.67(s,3H)),2.83-2.78(m,2H).13C NMR(126MHz,MeOD)δ172.89、149.00、127.61、125.56、124.68、67.55、52.22、45.23。
实施例40
2-羰基3-羟基戊酸甲酯(1af):70%产率[α]D25=-11.01(在MeOH中c=0.10),对映体过量:80%,Daicel Chiralpak OD,己烷/异丙醇=95/5,流速1.0mL/min,25℃:tR(主要)=
Figure GDA0002529905550000174
实施例41
3-羟基-5-苯基戊酸甲酯(1ag):产率72%,[α]D25=+18.97(CHCl3中c=0.26),对映体过量:
Figure GDA0002529905550000181
(m,1H),2.66–2.59(m,1H),2.41(qd,J=16.5,6.0Hz,2H),1.82–1.71(m,1H)),1.71–1.63(m,1H)。13C NMR(126MHz,CDCl3)δ173.33,141.70,128.45,128.43,125.91,67.25,51.73,41.16,38.12,31.76。
以上所揭露的仅为本发明较佳实施例而已,当然不能以此来限定本发明之权利范围,因此依本发明权利要求所作的等同变化,仍属本发明所涵盖的范围。

Claims (6)

1.一种手性β羟基酸酯类化合物的合成方法,其特征在于该方法包括:
以醛类化合物与丙二酸单烷基酯为原料,在有机溶剂中,以金属化合物、有机酸盐以及手性配体为催化剂,进行脱羧aldol加成反应,反应完毕后经过分离纯化得到的手性β羟基酸酯类化合物,该手性β羟基酸酯类化合物的结构式为:
Figure FDA0002529905540000011
所述醛类化合物的结构式为:
R1-CHO;
所述丙二酸单烷基酯的结构式为
Figure FDA0002529905540000012
所述的R1选自下列之一:烷基、带氟、氯、溴、硝基、烷基、烷氧基等取代的苯基或其它类芳基;
所述的R2选自下列之一:甲基、乙基、丙基、丁基、异丙基、叔丁基;
所用的有机溶剂为不与反应物和产物发生反应的有机溶剂;
所述的金属化合物为六水合氯化镍;
所述的有机酸盐为邻硝基苯甲酸钾;
所述的手性配体为以下结构式的化合物:
Figure FDA0002529905540000013
所述的脱羧aldol加成反应的温度为0-60℃。
2.根据权利要求1所述的手性β羟基酸酯类化合物的合成方法,其特征在于:所述的有机溶剂选自下列一种或者任意几种的组合:二氯甲烷、乙酸乙酯、四氢呋喃、乙腈、甲苯、甲醇、氯仿。
3.根据权利要求1所述的手性β羟基酸酯类化合物的合成方法,其特征在于:所用有机溶剂的质量是原料的1-200倍。
4.根据权利要求1所述的手性β羟基酸酯类化合物的合成方法,其特征在于:所述的醛类化合物与丙二酸单烷基酯的摩尔投料比为1:1-5。
5.根据权利要求1所述的手性β羟基酸酯类化合物的合成方法,其特征在于:所述的催化剂与醛类化合物比例为1wt%-20wt%,所述的催化剂体系中金属与手性配体的摩尔比为1:1-1.5。
6.根据权利要求2所述的一种手性β羟基酸酯类化合物的合成方法,其特征在于:所述的脱羧aldol加成反应的反应时间为3-120小时。
CN201811536129.9A 2018-12-14 2018-12-14 一种手性β羟基酸酯类化合物的合成方法 Active CN109734600B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201811536129.9A CN109734600B (zh) 2018-12-14 2018-12-14 一种手性β羟基酸酯类化合物的合成方法
US16/702,555 US10906860B2 (en) 2018-12-14 2019-12-04 Method for synthesizing chiral beta-hydroxy acid ester compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811536129.9A CN109734600B (zh) 2018-12-14 2018-12-14 一种手性β羟基酸酯类化合物的合成方法

Publications (2)

Publication Number Publication Date
CN109734600A CN109734600A (zh) 2019-05-10
CN109734600B true CN109734600B (zh) 2020-09-15

Family

ID=66359470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811536129.9A Active CN109734600B (zh) 2018-12-14 2018-12-14 一种手性β羟基酸酯类化合物的合成方法

Country Status (2)

Country Link
US (1) US10906860B2 (zh)
CN (1) CN109734600B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110204468B (zh) * 2019-05-31 2021-02-02 浙江工业大学 一种手性α-硫氰基环状酮酸酯类化合物的不对称合成方法
CN110256248B (zh) * 2019-06-25 2021-09-21 温州大学 2-(9,10-二氢菲-9-基)丙二酸酯的合成方法
CN112851513B (zh) * 2021-01-23 2022-10-28 温州大学新材料与产业技术研究院 一种3-羰基5-羟基酯类化合物的合成方法
CN114057785B (zh) * 2021-12-13 2023-03-28 河南师范大学 手性α-二氟甲基硅烷化合物的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108191664A (zh) * 2018-01-16 2018-06-22 温州大学 一种β羟基酸类化合物及其合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108191664A (zh) * 2018-01-16 2018-06-22 温州大学 一种β羟基酸类化合物及其合成方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biomimetic catalytic enantioselective decarboxylative aldol reaction of b-ketoacids with trifluoromethyl ketones;Yan Zheng;《Chem. Commun.》;20120309;第48卷;第4308-4310页 *
Enantioselective Synthesis of anti-β-Hydroxy-α-amino Esters via an Organocatalyzed Decarboxylative Aldol Reaction;Taryn March;《Synlett》;20170203;第28卷;第1295-1299页 *
Organocatalytic Enantioselective Decarboxylative Aldol Reaction of Malonic Acid Half Thioesters with Aldehydes;Han Yong Bae;《Angew. Chem. Int. Ed.》;20130923;第52卷;第12143-12147液 *
Stereoselective Direct Amine-Catalyzed Decarboxylative Aldol Addition;Kerstin Rohr;《ORGANIC LETTERS》;20110703;第13卷(第7期);第1878-1880页 *

Also Published As

Publication number Publication date
CN109734600A (zh) 2019-05-10
US10906860B2 (en) 2021-02-02
US20200190013A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CN109734600B (zh) 一种手性β羟基酸酯类化合物的合成方法
Reyes et al. How to make five contiguous stereocenters in one reaction: Asymmetric organocatalytic synthesis of pentasubstituted cyclohexanes
Takai et al. Reduction of acrolein dialkyl, acetals with CrCl2. γy-alkoxy substitued allylic chromium reagents for selective synthesis of erythro-1, 2-diols.
CN111205279B (zh) 一种多取代苯并二氢呋喃并杂环类化合物及其制备方法和应用
CN109942364B (zh) 一种以水为氢源的烯烃合成方法
Chang et al. Mannich-type reactions in a colloidal solution formed by sodium tetrakis (3, 5-trifluoromethylphenyl) borate as a catalyst in water
CN114805068B (zh) 一种手性α-羟基-β-酮酸酯化合物的制备方法
CN107954821A (zh) 一种钌催化二苄基甲酮与内炔环化反应制备多芳取代萘衍生物的方法及应用
EP1346977A1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
Yuan et al. Reaction of aldimines and difluoroenoxysilane, an unexpected protocol for the synthesis of 2, 2-difluoro-3-hydroxy-1-ones
CN108558635B (zh) 3-芳基丙炔酸类及3-芳基丙炔酸酯类化合物的制备方法
CN112264105B (zh) 一种用于取代酮和双酚f合成的负载型钯催化剂
CN112920072B (zh) Nobin类联芳基化合物及其合成方法
CN109232282B (zh) 一种2-氨基二苯甲酮类化合物的合成方法
CN106279014A (zh) 一种合成苯甘氨酸类衍生物及方法
CN108864173B (zh) 由取代的芳基亚磺酸钠转化为芳基三正丁基锡的方法
CN104945376A (zh) 一种3-芳酰基吲哚化合物的合成方法
CN103665036A (zh) 手性亚砜-膦化合物、制备及应用
CN109608390A (zh) 一种手性季碳吡啶类β羟基酯类化合物的合成方法
CN112521289B (zh) 一种氧杂烯丙基胺类化合物及其制备方法和应用
CN114195753B (zh) 一种钌催化一锅法制备3,4-二苯基异香豆素衍生物的制备方法
CN110256349B (zh) 多取代吡唑及其制备方法
CN114751800B (zh) 一种5-磺酰基戊-2,3-二烯腈化合物的合成方法
CN112851513B (zh) 一种3-羰基5-羟基酯类化合物的合成方法
CN110590641B (zh) 一种3-羟基异吲哚-1-酮系列化合物的绿色制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant